Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 1.96B +76.1% |
| Revenue (ttm) | 298.30M +20.6% |
| Net Income | 298.21M +648.4% |
| EPS | 2.17 +717.4% |
| Shares Out | 128.60M |
| PE Ratio | 7.00 |
| Forward PE | 15.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,541,826 |
| Open | 15.15 |
| Previous Close | 15.14 |
| Day's Range | 14.79 - 15.45 |
| 52-Week Range | 7.29 - 16.88 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 17.25 (+13.26%) |
| Earnings Date | May 7, 2026 |
About AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can... [Read more]
Financial Performance
In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 13.26% from the latest price.
News
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
Reports Q1 revenue $77.7M, consensus $76.98M. “Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief...
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.
Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies
After Aurinia Pharmaceuticals (AUPH) announced an agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus one non-transferable contingent value right, Jefferies said the deal ...
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
Aurinia Pharmaceuticals (AUPH) has entered into a definitive merger agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one non-transferable conting...
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value ...
MKT Capital ‘applauds’ Aurinia’s management transition
MKT Capital, a long-term shareholder of Aurinia Pharmaceuticals (AUPH), issued a statement in response to the company’s announcement that Kevin Tang has been appointed CEO. Antoine Khalife, Founder of...
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” o...
Aurinia Pharmaceuticals announces Tang to succeed Greenleaf as CEO
Aurinia Pharmaceuticals (AUPH) announced that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the t...
Aurinia Announces Management Transition
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.
Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2025
LUPKYNIS sales grew 25% year-over-year in 2025, driving a 20% revenue increase and a dramatic rise in net income, aided by a significant tax benefit. 2026 guidance projects continued double-digit growth, with new clinical programs advancing and competition expected to expand the market.
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
Reports Q4 revenue $77.1M, consensus $74.7M. As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $398.0M vs. $358.5M at December 31, 2024. “We are
Aurinia Pharmaceuticals sees 2026 revenue $315M-$-325M, consensus $326.8M
06:07 EST Aurinia Pharmaceuticals (AUPH) sees 2026 revenue $315M-$-325M, consensus $326.8M
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided ...
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31...
Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a price target of $16, up from $15. While Aurinia has done well with the commercialization of Lupkynis in
Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a $16 price target
Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance with Lupkynis has driven a strong balance sheet
Aurinia downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Aurinia Pharmaceuticals (AUPH) to Sector Perform from Outperform with a price target of $15, up from $9. The firm says the shares have doubled over the last
Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2025
LUPKYNIS sales surged 27% year-over-year in Q3 2025, prompting a second upward revision of 2025 guidance. New clinical data reinforced LUPKYNIS's efficacy and safety, while Aritinercept advanced toward clinical studies in two autoimmune diseases.
Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 16c
Reports Q3 revenue $73.5M, consensus $67.7M. “LUPKYNIS sales experienced continued momentum following last year’s update to the American College of Rheumatology lupus nephritis treatment guidelines, w...
Aurinia Pharmaceuticals raises FY25 revenue view to $275M-$280M from $260M-$270M
FY25 consensus $270.48M. For 2025, Aurinia is increasing total revenue guidance from a range of $260 million to $270 million to a range of $275 million to $280 million and
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided ...
FDA official resigns, sued by Aurinia Pharmaceuticals, WSJ reports
An FDA official who recently resign is being sued by Aurinia Pharmaceuticals (AUPH) for allegedly soliciting a bribe and tanking its stock with false statements in a revenge campaign against
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30,...
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.